Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03557359
Title Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University
Indications

high grade glioma

Therapies

Nivolumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Miami Cancer Center Miami Florida 33176 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Columbia University Medical Center New York New York 10032 United States Details
Weill Cornell Medical College New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field